Objective: To determine the efficacy and safety of percutaneous aspiration and steroid injection treatment for ganglion cysts and retrospectively evaluate the size change in ganglion cysts during follow-up.
Material and Method: All patients who underwent percutaneous aspiration and steroid injection treatment for ganglion cysts between January 2019 and February 2020 were included in the study. Demographic characteristics and clinical signs and findings of the patients were obtained from electronic patient records. Treatment response was classified as “excellent,” “good,” and “poor” at one month and one year according to ultrasound measurement.
Results: Ganglion cyst aspiration and steroid injection were successfully performed in 37 (86.0%) of 43 cases. A total of 28 cases with short- and long-term follow-ups were included in the final analysis. All the cases had cosmetic complaints before the treatment, and seven had pain and four had limited range of motion. Early treatment response was excellent in 7 (25.0%) patients, good in 14 (50.0%), and poor in 7 (50.0%). Late treatment response was excellent in 18 (64.3%) patients, good in 3 (10.7%), and poor in 7 (25.0%). After the procedure, mild pain lasting less than two days developed in the cyst area in half of the patients. Skin color change was observed in two cases in the first-month follow-up.
Conclusion: Ultrasound-guided fine-needle aspiration and steroid injection with the right technique is an alternative cost-effective method to surgery that can be successfully applied in the treatment of ganglion cysts with low side effects and relatively good results.
N/A
N/A
N/A
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Original Article |
Authors | |
Project Number | N/A |
Publication Date | January 17, 2022 |
Published in Issue | Year 2022 Volume: 5 Issue: 1 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.